Athersys (NASDAQ:ATHX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a research report report published on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The stock has a market cap of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a one year low of $0.01 and a one year high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.